← Leaderboards
Dorothy Anne Cross
Washington University
$5,584,847
Attributed
$5,584,847
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$16,910,569 · 11
By mechanism
P01$14,948,925 · 5
R01$1,360,616 · 2
K24$347,433 · 1
R03$157,500 · 1
M01$96,095 · 2
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Clifford M Will$2,550,248
- Manel Errando$2,649,505
- Yajie Yuan$666,393
- James H Buckley$492,741
- Ramki Kalyanaraman$3,767,148
Others in their field
Top investigators on “Myelin”
- James J Lah · Emory University$35,158,235
- Stephen Arthur Back · Oregon Health & Science University$23,494,618
- Vijay K Kuchroo · Brigham And Women'S Hospital$22,841,024
- Jeff W Lichtman · Washington University$21,489,807
- Bruce D Trapp · Cleveland Clinic Lerner Com-Cwru$21,079,355
- Brian J Popko · Northwestern University$20,097,136
Research focus
MyelinMultiple SclerosisImageResearch PersonnelPathogenesisMagnetic Resonance ImagingNeurologyInflammationPathologyBaseLesionBrainProgramsCommunicationAffectPerformanceDemyelinationsMeetingsProgram Research Project GrantsDiffusionBiological MarkersMouse ModelInjuryWhite Matter
Grant awards (45)
Using quantitative gradient echo MRI to distinguish MOG antibody disorder from multiple sclerosis$157,500
R03 · FY2021 · NS · contact PI
Biomarkers and Pathogenesis of MS: From Mouse to Human$1,208,803
P01 · FY2018 · NS · contact PI
BIOMARKERS AND PATHOGENESIS OF MS: FROM MOUSE TO HUMAN$321,685
P01 · FY2018 · NS · contact PI
Administrative and Statistics Core$72,695
P01 · FY2018 · NS · contact PI
Biomarkers and Pathogenesis of MS: From Mouse to Human$1,222,742
P01 · FY2017 · NS · contact PI
BIOMARKERS AND PATHOGENESIS OF MS: FROM MOUSE TO HUMAN$327,551
P01 · FY2017 · NS · contact PI
Administrative and Statistics Core$72,695
P01 · FY2017 · NS · contact PI
Biomarkers and Pathogenesis of MS: From Mouse to Human$1,236,151
P01 · FY2016 · NS · contact PI
BIOMARKERS AND PATHOGENESIS OF MS: FROM MOUSE TO HUMAN$333,046
P01 · FY2016 · NS · contact PI
Administrative and Statistics Core$72,695
P01 · FY2016 · NS · contact PI
Biomarkers and Pathogenesis of MS: From Mouse to Human$1,236,709
P01 · FY2015 · NS · contact PI
BIOMARKERS AND PATHOGENESIS OF MS: FROM MOUSE TO HUMAN$331,369
P01 · FY2015 · NS · contact PI
Administrative and Statistics Core$75,561
P01 · FY2015 · NS · contact PI
Biomarkers and Pathogenesis of MS: From Mouse to Human$1,237,891
P01 · FY2014 · NS · contact PI
BIOMARKERS AND PATHOGENESIS OF MS: FROM MOUSE TO HUMAN$331,731
P01 · FY2014 · NS · contact PI
Administrative and Statistics Core$75,519
P01 · FY2014 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$992,711
P01 · FY2012 · NS · contact PI
Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)$247,312
P01 · FY2012 · NS · contact PI
Administrative and Statistics Core$96,418
P01 · FY2012 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$982,140
P01 · FY2011 · NS · contact PI
Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)$220,819
P01 · FY2011 · NS · contact PI
Administrative and Statistics Core$94,559
P01 · FY2011 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$1,096,999
P01 · FY2010 · NS · contact PI
Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)$237,409
P01 · FY2010 · NS · contact PI
Administrative and Statistics Core$101,670
P01 · FY2010 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$1,092,899
P01 · FY2009 · NS · contact PI
Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)$221,036
P01 · FY2009 · NS · contact PI
Administrative and Statistics Core$107,524
P01 · FY2009 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$26,959
P01 · FY2009 · NS · contact PI
Biomarkers and Pathogenesis of Multiple Sclerosis: From Mouse to Human$991,718
P01 · FY2008 · NS · contact PI
Directional Diffusivity as a Window into the Pathology of Multiple Sclerosis (MS)$186,504
P01 · FY2008 · NS · contact PI
Administrative and Statistics Core$95,405
P01 · FY2008 · NS · contact PI
A Phase ll Trial of Rituxan In Multiple Sclerosis$89,986
K24 · FY2007 · RR · contact PI
A PHASE II TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$8,132
M01 · FY2007 · RR · contact PI
A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$88,100
K24 · FY2006 · RR · contact PI
A PHASE II TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$28,321
M01 · FY2006 · RR · contact PI
A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$85,794
K24 · FY2005 · RR
A PHASE II TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$31,218
M01 · FY2005 · RR
THE ROLE OF B CELLS IN EAE PATHOGENESIS$327,038
R01 · FY2004 · NS
A PHASE II TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS$83,553
K24 · FY2004 · RR
A Phase II Trial of Rituxan in Multiple Sclerosis.$28,424
M01 · FY2004 · RR
THE ROLE OF B CELLS IN EAE PATHOGENESIS$327,038
R01 · FY2003 · NS
THE ROLE OF B CELLS IN EAE PATHOGENESIS$327,038
R01 · FY2002 · NS
EFFECTOR MOLECULES IN DEMYELINATING DISEASE$190,102
R01 · FY2001 · NS
EFFECTOR MOLECULES IN DEMYELINATING DISEASE$189,400
R01 · FY2000 · NS